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Abstract
Background: Patients with tuberculosis require retreatment if they fail or default from initial treatment or if they
relapse following initial treatment success. Outcomes among patients receiving a standard World Health
Organization Category II retreatment regimen are suboptimal, resulting in increased risk of morbidity, drug
resistance, and transmission. In this study, we evaluated the risk factors for initial treatment failure, default, or early
relapse leading to the need for tuberculosis retreatment in Morocco. We also assessed retreatment outcomes and
drug susceptibility testing use for retreatment patients in urban centers in Morocco, where tuberculosis incidence
is stubbornly high.
Methods: Patients with smear- or culture-positive pulmonary tuberculosis presenting for retreatment were
identified using clinic registries in nine urban public clinics in Morocco. Demographic and outcomes data were
collected from clinical charts and reference laboratories. To identify factors that had put these individuals at risk for
failure, default, or early relapse in the first place, initial treatment records were also abstracted (if retreatment began
within two years of initial treatment), and patient characteristics were compared with controls who successfully
completed initial treatment without early relapse.
Results: 291 patients presenting for retreatment were included; 93% received a standard Category II regimen.
Retreatment was successful in 74% of relapse patients, 48% of failure patients, and 41% of default patients. 25% of
retreatment patients defaulted, higher than previous estimates. Retreatment failure was most common among
patients who had failed initial treatment (24%), and default from retreatment was most frequent among patients
with initial treatment default (57%). Drug susceptibility testing was performed in only 10% of retreatment patients.
Independent risk factors for failure, default, or early relapse after initial treatment included male gender (aOR =
2.29, 95% CI 1.10-4.77), positive sputum smear after 3 months of treatment (OR 7.14, 95% CI 4.04-13.2), and
hospitalization (OR 2.09, 95% CI 1.01-4.34). Higher weight at treatment initiation was protective. Male sex, substance
use, missed doses, and hospitalization appeared to be risk factors for default, but subgroup analyses were limited
by small numbers.
Conclusions: Outcomes of retreatment with a Category II regimen are suboptimal and vary by subgroup. Default
among patients receiving tuberculosis retreatment is unacceptably high in urban areas in Morocco, and patients
who fail initial tuberculosis treatment are at especially high risk of retreatment failure. Strategies to address risk
factors for initial treatment default and to identify patients at risk for failure (including expanded use of drug
susceptibility testing) are important given suboptimal retreatment outcomes in these groups.
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Tuberculosis (TB) continues to be a global public health
problem, with an estimated 9.4 million incident cases of
TB and 1.8 million deaths in 2008 [1]. Drug resistance
and obstacles to successful directly observed therapy
short-course (DOTS) impede disease control. Among
patients being retreated for TB because of initial treat-
ment failure, default from initial treatment, or relapse
following initial treatment, drug resistance is common
and retreatment outcomes inferior [2,3].
Patients who fail, default from, or relapse after com-
pletion of standard first-line TB treatment and present
for retreatment were previously grouped together by
the World Health Organization (WHO) as Category II
cases, and, in settings where individual drug suscept-
ibility testing (DST) was not universally accessible,
these patients were often treated with a standard
retreatment regimen of first-line agents (a regimen
that adds a single drug to the standard initial TB
treatment regimen) [4]. Retreatment outcomes, how-
ever, are often poor, especially in patients with treat-
ment failure or default [5]. DST may help identify
those patients with multidrug-resistant (MDR) TB so
that the appropriate antibiotics can be administered.
Identifying local patient characteristics that confer
higher risk of relapse, failure, or default from primary
TB treatment may help inform country-specific pre-
vention strategies aiming to reduce the need for
retreatment, resulting in cost savings and diminished
morbidity and transmission.
In Morocco, the incidence of TB in 2008 was 81 per
100,000 overall but was significantly higher in several
urban centers, or “hot spots”. Of the roughly 28,000
new TB cases nationally each year, 12% are retreatment
cases [5]. National TB treatment guidelines in 2007 and
2008 recommended a Category I treatment regimen – 2
months of isoniazid, rifampin, pyrazinamide, and strep-
tomycin followed by 4 months of rifampin and isoniazid
(2SHRZ/4RH) – for new smear-positive cases and a
Category II regimen – 2HRZES/1RHEZ/5RHE (E =
ethambutol) – for retreatment cases. Beginning in 2009,
ethambutol replaced streptomycin in Category I regi-
mens. Among retreatment cases in Morocco, 12.2% are
infected with Mycobacterium tuberculosis strains that
are resistant to rifampin and isoniazid, or MDR TB [6].
National guidelines suggest drug susceptibility testing
(DST) for all retreatment patients.
This retrospective cohort study examines the efficacy
of standard TB retreatment in urban centers in Mor-
occo, evaluates the uptake of DST testing for retreat-
ment patients, and, using a nested case-control design,
explores the risk factors that led to the need for retreat-
ment in the first place.
Methods
Sites
Morocco’s National Tuberculosis Program (NTP) is
well-established. TB care is provided free of charge by
the Ministry of Health. Regional TB programs are
divided into sectors, and each sector has a public health
center (CDTMR) staffed by a specialist in TB care. TB
clinical care is provided at CDTMR, while TB medica-
tions are delivered via DOTS at local clinics or dispen-
saries. M. tuberculosis culture and DST are performed
at the National Reference Laboratory at the National
Institute of Hygiene (INH) in Rabat or at the regional
reference laboratory at the Institute Pasteur in Casa-
blanca (IPM). National guidelines recommend DST for
all retreatment patients. We chose nine urban CDTMR
in high-incidence settings in Rabat, Casablanca, Fes,
Tangier, and El Jedida as sites.
Design
A retrospective cohort study of retreatment cases focus-
ing on patient characteristics, treatment outcomes, and
drug susceptibility was conducted. To determine the
risk factors for failure, relapse, or default after initial
treatment that led to the need for retreatment, a nested
case-control study was performed.
Study population
Moroccan patients with smear- or culture-confirmed
pulmonary TB presenting for retreatment between June
2007 and August 2008 were identified using clinic regis-
tries. Those who had failed initial treatment, had relapse
after completing initial treatment, or defaulted after at
least two months of initial treatment were included in
the cohort study. Among patients in the cohort study,
those whose initial treatment had ended within two
years of starting their retreatment regimen were eligible
to be included in the nested case-control study as cases.
The rationale for the two-year limit was to make it
more likely that initial treatment charts would be avail-
able, to ensure that standards of practice for initial TB
treatment would be similar across cases, and to increase
the likelihood that recurrent disease represented relapse
rather than reinfection. Controls were chosen from
among patients with successful initial treatment without
failure, default, or early relapse selected from the same
center and treatment week.
Definitions
As per national guidelines, a patient with positive spu-
tum smears for acid-fast bacilli after 5 months of con-
tinuous Category I treatment had treatment failure.
A patient with initial treatment success after TB therapy
of sufficient length (9 months for severe disease,
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had treatment relapse. Treatment default was defined as
interruption of treatment for ≥2 consecutive months.
Treatment success was defined as treatment completion
or cure. Retreatment patients were those receiving their
first retreatment regimen after relapse, failure, or
default.
Data collection
DST results were reviewed at INH and IPM to identify
sites that used DST testing services. At clinics chosen as
study sites, the TB registry and medical records of
included patients were reviewed. For retreatment
patients, information from initial TB treatment was col-
lected if initial treatment was within two years of
retreatment, and this information was used for risk fac-
tor analyses. This study was approved by the Ministry of
Health of Morocco and by the Institutional Review
Board of the Johns Hopkins University School of
Medicine.
Drug Susceptibility Testing
Smear microscopy and culture were performed using
standard methods. Specimens demonstrating growth of
M. tuberculosis on Lowenstein-Jensen medium were
tested for susceptibility to isoniazid, rifampin, ethambu-
tol, and streptomycin using the proportion method. Cri-
tical concentrations were as follows: RIF 40 mcg/mL,
INH 0.2 mcg/mL, streptomycin 4 mcg/mL, and etham-
butol 2 mcg/mL. DST quality control was provided by
the Supranational Laboratory at the Institute Pasteur of
Algiers, as per standard laboratory operating procedures.
Statistical analysis
Data analyses were performed in EpiInfo™ (Version
3.3.2, Centers for Disease Control, Atlanta, GA) except
for multivariate logistic regressions, which were per-
formed using STATA software, version 10.0 (StataCorp
LP, College Station, Texas). Demographic and clinical
characteristics of cases and controls during initial TB
treatment were compared using Pearson’s c
2 or Fisher’s
exact tests for categorical variables and student’s t tests
for continuous variables. Variables known to be risk fac-
tors for relapse, failure, or default as well as factors
found to be associated with these outcomes in univariate
analyses were included in multivariable logistic regres-
sion models. Significance tests were two-sided with p-
values of ≤ 0.05 considered statistically significant.
Results
Tuberculosis retreatment patients: population description,
treatment outcomes, and DST results
291 patients with smear- or culture-positive pulmonary
TB presenting for retreatment were identified and
included in the study. Of retreatment cases, 232 (80%)
had relapsed after completing an initial treatment regi-
men, 21 (7%) had failed an initial treatment regimen,
and 38 (13%) had defaulted from initial treatment. The
mean age was 37 years (IQR 27-46), and 78% were men.
HIV and diabetes mellitus were rare (recorded for 1 and
3 patients, respectively).
A standard Category II retreatment regimen was used
in 272 (93%) of 291 patients. Retreatment outcomes
were as follows: 172 (59%) cured, 26 (9%) completed
treatment, 7 (2%) died, 73 (25%) defaulted, and 11 (4%)
failed. Retreatment was successful in 173 (74%) of
relapse patients, 10 (48%) of failure patients, and 15
(41%) of default patients.(p < 0.01) Not surprisingly,
retreatment failure was more common among patients
who had failed initial treatment (24%) than among
relapse (3%) or default (0%) patients (p < 0.01). Default
was very common among retreatment patients at 25%
overall and was particularly high among patients with
initial treatment default (57%) (vs. 20% among relapse
patients and 24% among failure patients (p < 0.01)).
Among relapse patients, the median time from the end
of initial treatment to diagnosis of relapse was 7.0 years
(range 9 months to 44 years).
Only 30 (10%) of 291 retreatment patients had DST
testing performed with results available in the chart. Of
three patients being retreated because of initial treat-
ment failure who were tested, all had resistance to HRS,
none of five being retreated because of default from
initial treatment who were tested had pan-sensitive
M. tuberculosis,a n d3o f2 2( 1 4 % )p a t i e n t sw h ow e r e
being retreated because of relapse within two years after
initial TB treatment had MDR-TB.
Risk factors for relapse, failure, or default from initial TB
treatment: results of the nested case-control study
Of 291 retreatment patients, 104 (36%) had started a
retreatment regimen within two years of completing or
stopping initial TB treatment and were, thus, eligible for
the risk factor analysis. Of these, initial treatment charts
were available for 83 (80%), and 80 were suitable for
data extraction (cases, n = 80). 266 patients with initial
treatment success were included as controls (controls,
n = 266). (Table 1).
In a multivariable logistic regression analysis, patients
undergoing initial treatment for TB were at higher risk
of a composite endpoint of failure, default, or relapse
w i t h i nt w oy e a r si ft h e yw e r em a l e( O R=2 . 2 9 ,9 5 %C I
1.10-4.77), failed to have sputum smear conversion to
negative by 3 months of treatment (OR 7.14, 95% CI
4.04-13.2), or required hospitalization during treatment
(OR 2.09, 95% CI 1.01-4.34). There was a trend towards
increased risk of this composite endpoint among those
with poor weight gain (less than 10% by two months of
Dooley et al. BMC Public Health 2011, 11:140
http://www.biomedcentral.com/1471-2458/11/140
Page 3 of 7treatment) or missed doses during the intensive phase of
treatment, but these differences did not reach statistical
significance. Odds of the composite outcome were 4%
l o w e rf o re a c h1k i l o g r a mi n c r e a s ei nw e i g h ta tt r e a t -
ment initiation (OR 0.96, 95% CI 0.93-0.99). Alcohol use
and HIV were uncommon (2% and <1%, respectively).
Risk factors appeared to differ by subgroup, though
analyses were limited by sample size (Table 2). Risk fac-
tors for treatment default included male sex, substance
use, missed doses during the intensive phase, and hospi-
talization. Risk factors for failure or relapse were harder
to identify.
Discussion
In this study of 291 patients undergoing retreatment for
TB, outcomes differed considerably by group – 74% of
patients with relapse, 48% of patients with failure, and
41% of patients with default had treatment success –
similar to previous studies [5,7]. Default from
retreatment was extremely common at 25%, higher than
previous country-wide estimates [5]. This may reflect
temporal changes in treatment completion but more
likely represents differences in study populations, as we
focused on TB “hot spots”, or urban centers with com-
paratively high TB incidence. Recent studies have
demonstrated that, in urban settings, adherence is linked
to patient knowledge about TB and provision of disease-
specific education by the health care provider to the
patient [8]. In busy urban clinics, time for education may
be limited. Default from retreatment was most frequent
among those who had defaulted from initial treatment,
while failure was most common among those with pre-
vious failure. Although retreatment guidelines are often
the same for patients with failure, default from, or relapse
after initial treatment, [4] these results suggest that
groups may benefit from different management strategies
[9,10]. For example, treatment failure is commonly due
to drug resistance, while recurrence may be due to poor
Table 1 Patient and disease characteristics of individuals receiving standard initial tuberculosis treatment, comparing
patients with treatment relapse, failure, or default (cases) to patients with treatment success without relapse
(controls)
Characteristic Cases
(N = 80)
Controls
(N = 266)
p-value
At treatment initiation
Male gender (n, %) 65 (81) 175 (66) < 0.01
Marital status (n, %)§ 0.70
Single 32 (59) 101 (53)
Married 21(39) 85(45)
Other (widowed, divorced) 1(2) 4(2)
Medical comorbidities (n,%)* 13(16) 30(11) 0.23
Cavity on chest x-ray (n,%)‡ 32(46) 101(43) 0.65
Age (mean, sd) 33.2(13.6) 34.5(14.3) 0.47
Weight at treatment initiation (mean, sd) 55.1 (9.5) 56.0 (9.4) 0.46
Habits (n, %)√
Tobacco use 18 (23) 42(16) 0.16
Alcohol use 2(3) 6(2) 0.89
Illicit drug use 6(8) 4(2) < 0.01
During treatment
Sputum smear conversion to negative by 3 months (n,%)† 28(45) 220 (87) < 0.01
Weight gain after two months of treatment (kg, sd)** 2.6 (3.8) 3.4 (3.6) 0.09
Weight gain over initial treatment period (5-6 months) (kg, sd)** 3.8 (5.8) 6.6 (5.3) < 0.01
Missed doses during intensive phase 14(18) 10(4) < 0.01
Hospitalization 21(26) 38(14) 0.01
§N = 54 for cases, 190 for controls, as marital status was not consistently recorded in the charts.
*Patients with no evidence of comorbid conditions in chart review were combined with those for whom the absence of cormorbidities was expressly noted.
‡N = 70 for cases, 237 for controls, as x-rays were not performed and recorded for all patients.
√Patients with no evidence of tobacco, alcohol, or illicit drug use in chart review were combined with those for whom the absence of tobacco, alcohol, or illicit
use was expressly noted.
†N = 62 for cases (15 of 27 patients with default did not have sputum smear conversion data, 3 patients with relapse were culture-positive, smear-negative
cases); N = 251 for controls.
**N = 65 for cases (12 default patients, 1 failure, and 2 relapse patients did not have 2-month weight data), 263 for controls at 2 months; n = 50 for cases, 257
for controls after 5-6 months of treatment.
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tary disease), or exogenous reinfection. Default patients
may require intensified case management and education,
rather than more intensive treatment.
The present study shows that, even when available,
drug susceptibility testing is underutilized. It was per-
formed in only 10% of retreatment patients. All 3 failure
patients who underwent DST testing had MDR-TB,
while 3 of 22 of relapse patients and 0 of 5 default
patients tested did. While these DST results were only
available for three failure patients and, therefore, not
representative, these data and those from other studies
suggest that MDR risk is not uniform among retreat-
ment subgroups, with increased prevalence of MDR
among patients with initial treatment failure [2,11-13].
According to a population-based study conducted
among retreatment cases in Morocco, 12.2% had MDR-
TB, but the study did not divide retreatment patients
into failure, relapse, or default subgroups [6]. Taken
together, these findings support use of DST in all
retreatment patients, earlier DST testing in those with
clinical and microbiological indications of impending
treatment failure, and use of second-line drugs for
retreatment of patients with initial treatment failure
until DST results are known. In Morocco, DOTS cover-
age is 100%, and concerted efforts to dramatically
enhance DST use are underway.
Published medical risk factors for failure or relapse
include HIV infection, diabetes mellitus, low body
weight, cavitation on chest x-ray, high bacterial burden,
short treatment duration, drug resistance, and positive
culture after two months of treatment [14-16]. Sociode-
mographic factors include unemployment, drug abuse,
alcoholism, smoking, and poor treatment adherence.
Treatment default is known to be associated with sub-
stance abuse, foreign birth, male gender, previous
default, low socioeconomic status, psychiatric illness,
unemployment, migration, side effects, [17,18] long -
distance to the clinic, social stigma, and poorly-
implemented DOTS but, of course, differ by setting
[16,19-21]. In our study population, HIV infection is
rare; among TB patients, less than 1% are HIV-infected
(unpublished data, Morocco NTP). Further, alcohol use
in Morocco is uncommon, and smoking is extremely
uncommon among women. Moreover, in the urban
clinics studied, the majority of patients are non-immi-
grants, the clinics are geographically accessible, and
DOTS coverage is 100%. Thus, many traditional risk
factors for poor TB treatment outcomes are less promi-
nent in Morocco, making it harder to prospectively
identify patients at risk. However, continued sputum
smear positivity after 3 months of treatment is a strong
predictor of subsequent poor outcomes, and should
prompt DST testing in all patients. As missed treatment
doses may herald impending default, enhanced commu-
nication between the local clinics that dispense TB
treatment and physicians at the regional health centers
that prescribe it may be one country-specific strategy to
help pinpoint those individuals who are missing doses
and are at high risk of defaulting altogether. Small sam-
ple sizes limited our ability to evaluate subgroups, but
e v e ns o ,w ew e r ea b l et oi d e n t i f ym a l es e x ,s u b s t a n c e
use (tobacco, alcohol, or illicit drug use), and missed
doses during the intensive phase as likely risk factors for
treatment default. Higher odds of hospitalization prob-
ably reflected the need for hospitalization to ensure
adherence rather than increased disease severity. Further
exploring risk factors for treatment default may help
control programs identify those likely to benefit from
targeted interventions such as health education, sub-
stance abuse counseling, enhanced tracking, or reinfor-
cement of DOTS supervision [22,23].
Table 2 Risk factors for relapse, failure, or default from initial TB treatment, a subgroup analysis
Subgroup
Risk factor
Univariate analysis
(OR, 95% CI)
Multivariate analysis
(OR, 95% CI)
Relapse (N = 35)
Lack of sputum smear conversion to negative by 3 months 4.58 (2.22-9.43) 4.14 (1.92-9.01)
Missed doses during the intensive phase 3.23 (0.96-10.9) NS
Treatment failure (N = 18)
Lack of sputum smear conversion to negative by 3 months ** **
Comorbid conditions 3.29 (1.08-9.99) NS
Treatment default (N = 27)
Male gender 6.50 (1.51-28.1) 4.56 (0.96-20.7)
Substance use† 4.19 (1.83-9.56) 2.73 (1.04-7.15)
Missed doses during the intensive phase 12.9 (4.65-35.7) 10.9 (3.47-34.0)
Hospitalization during treatment 2.56 (1.04-6.23) 3.84 (1.41-10.5)
** Three-month sputum smear conversion to negative was negative in all failure patients so could not be included in logistic regression models.
†Tobacco, alcohol, or illicit drug use.
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tion was limited by the availability of data present in clin-
ical charts. Information about tobacco, alcohol, and illicit
drug use was not routinely recorded, for example. Classi-
fying those with missing substance use data as nonusers
likely biased analyses of this risk factor toward the null;
however, estimates of smoking, tobacco, and illicit drug
use were similar to national substance use statistics [24].
Also, in cases of recurrence, it was not possible to distin-
guish between relapse and reinfection, so we limited our
risk factor analysis to those who had received initial TB
treatment within two years of recurrence and were, thus,
more likely to have true relapse. Our ability to identify
independent risk factors in subgroup analyses was limited
by small sample sizes; questions regarding risk factors in
these subgroups would best be answered in larger, pro-
spective studies. Finally, DST testing was not universally
performed in retreatment patients, so selection bias is
possible, as clinicians are more likely to send those at
high risk of resistance for testing. In our study, 20% of
retreatment patients with DST had MDR-TB, compared
with 12% in a national prevalence survey [6].
Conclusions
Patients presenting for TB retreatment - those with
relapse, failure of initial treatment, or default – are often
grouped together and treated with a standard Category II
retreatment regimen. However, these groups have distinct
demographic and clinical characteristics, important differ-
ences in retreatment outcomes, and likely have different
rates of drug resistant M. tuberculosis. Default from
retreatment is common in high-incidence urban centers in
Morocco, pointing to the need for strategies to address
adherence. DST is essential for identifying retreatment
patients with drug resistance, but even when available, it is
underutilized, likely due to practical constraints. Prevent-
ing the need for retreatment in the first place is the best
strategy given the individual and public health conse-
quences of poor initial TB treatment outcomes, so strate-
gies to identify and address country-specific risk factors
are warranted to maximize treatment success.
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